Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis

Journal of the Chinese Medical Association

Volumn 75, Issue 7, 2012, Pages 303-308

  Chen, Wei Sheng ^a,b   Chang, Yu Sheng ^b,c   Lin, Kuan Chia ^d   Lai, Chien Chih ^a,b   Wang, Shu Hung ^a,b   Hsiao, Kai Hung ^b,e   Lee, Hui Ting ^b,f   Chen, Ming Han ^a,b   Tsai, Chang Youh ^a,b   Chou, Chung Tei ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ankylosing spondylitis; C reactive protein; Erythrocyte sedimentation rate; Interleukin 17; Interleukin 23

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PATHOGENESIS; PHYSICAL MOBILITY; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

EID: 84864093247     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.05.006     Document Type: Article

References (30)

1. Zochling J., Brandt J., Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 2005, 44:1483-1491.
2. Bal A., Unlu E., Bahar G., Aydog E., Eksioglu E., Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007, 26:211-215.
3. Wailoo A., Bansback N., Chilcott J. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology (Oxford) 2008, 47:119-120.
4. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
5. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
6. Wong C.K., Ho C.Y., Li E.K., Lam C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593.
7. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463.
8. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
9. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
10. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007, 25:221-242.
11. Layh-Schmitt G., Colbert R.A. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008, 20:392-397.
12. Wang X., Lin Z., Wei Q., Jiang Y., Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009, 29:1343-1347.
13. Wendling D., Cedoz J.-P., Racadot E., Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007, 74:304-305.
14. Wendling D., Cedoz J.-P., Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 2009, 28:187-190.
15. Shen H., Goodall J.C., Hill Gaston J.S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009, 60:1647-1656.
16. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
17. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
18. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
19. Jones S.D., Steiner A., Garrett S.L., Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996, 35:66-71.
20. Jandus C., Bioley G., Rivals J.-P., Dudler J., Speiser D., Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008, 58:2307-2317.
21. Sheehan N.J., Slavin B.M., Donovan M.P., Mount J.N., Mathews J.A. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 1986, 25:171-174.
22. Ruof J., Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999, 26:966-970.
23. Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999, 26:980-984.
24. Chen C.H., Lin K.C., Yu D.T., Yang C., Huang F., Chen H.A., et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006, 45:414-420.
25. Tam L.-S., Gu J., Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010, 6:399-405.
26. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997, 181:257-266.
27. Taylan A., Sari I., Kozaci D., Yuksel A., Bilge S., Yildiz Y., et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int 2011, [Epub ahead of print].
28. Korn T., Oukka M., Kuchroo V., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007, 19:362-371.
29. Roark C.L., Simonian P.L., Fontenot A.P., Born W.K., O'Brien R.L. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008, 20:353-357.
30. Hueber A.J., Asquith D.L., Miller A.M., Reilly J., Kerr S., Leipe J., et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010, 184:3336-3340.